UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 98

Sortiert nach

Interaction of Ritonavir-Boosted Tipranavir with Loperamide Does Not Result in Loperamide-Associated Neurologic Side Effects in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2005-12, Vol.49 (12), p.4903-4910

2005

Volltextzugriff (PDF)

Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers

Current HIV research, 2011-06, Vol.9 (4), p.237

2011

Volltextzugriff (PDF)

Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open‐Label, Fixed‐Sequence, Crossover Study

Basic & clinical pharmacology & toxicology, 2018-07, Vol.123 (1), p.84-93

2018

Volltextzugriff (PDF)

Interaction Studies of Tipranavir-Ritonavir with Clarithromycin, Fluconazole, and Rifabutin in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2009-01, Vol.53 (1), p.162-173

2009

Volltextzugriff (PDF)

Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes

Drug metabolism and disposition, 2016-03, Vol.44 (3), p.466-475

2016

Volltextzugriff (PDF)

Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers

Antimicrobial agents and chemotherapy, 2015-01, Vol.59 (1), p.514-519

2015

Volltextzugriff (PDF)

Steady-State Disposition of the Nonpeptidic Protease Inhibitor Tipranavir when Coadministered with Ritonavir

Antimicrobial Agents and Chemotherapy, 2007-07, Vol.51 (7), p.2436-2444

2007

Volltextzugriff (PDF)

Nevirapine Extended-Release Formulation Tablets in HIV-1–Infected Children—Long-term Follow-up

Clinical infectious diseases, 2015-08, Vol.61 (3), p.476-479

2015

Volltextzugriff (PDF)

Clinical Assessment of Potential Drug Interactions of Faldaprevir, a Hepatitis C Virus Protease Inhibitor, With Darunavir/Ritonavir, Efavirenz, and Tenofovir

Clinical infectious diseases, 2014-11, Vol.59 (10), p.1420-1428

2014

Volltextzugriff (PDF)

Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis

Antimicrobial agents and chemotherapy, 2015-02, Vol.59 (2), p.1282-1291

2015

Volltextzugriff (PDF)

Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation

Journal of clinical pharmacology, 2015-04, Vol.55 (4), p.467-477

2015

Volltextzugriff (PDF)

Steady-state Pharmacokinetics of Nevirapine Extended-release Tablets in HIV-1–infected Children and Adolescents: An Open-label, Multiple-dose, Cross-over Study

The Pediatric infectious disease journal, 2014-07, Vol.33 (7), p.e173-e179

2014

Volltextzugriff (PDF)

Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone

Drug and alcohol dependence, 2009-12, Vol.105 (3), p.234-239

2009

Volltextzugriff (PDF)

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity : sub-analysis from RESIST

AIDS (London), 2007-09, Vol.21 (14), p.1977-1980

2007

Volltextzugriff (PDF)

Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers

European journal of clinical pharmacology, 2011-03, Vol.67 (3), p.277-281

2011

Volltextzugriff (PDF)

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection

HIV clinical trials, 2017-11, Vol.18 (5-6), p.189-195

2017

Volltextzugriff (PDF)

Nevirapine Extended-Release Formulation Tablets in HIV-1–Infected Children—Long-term Follow-up: Table 1

Clinical infectious diseases, 2015-08, Vol.61 (3), p.476-479

2015

Volltextzugriff (PDF)

Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers

HIV clinical trials, 2004-11, Vol.5 (6), p.371-382

2004

Volltextzugriff (PDF)

Pharmacokinetic Characterization of Three Doses of Tipranavir Boosted with Ritonavir on Highly Active Antiretroviral Therapy in Treatment-Experienced HIV-1 Patients

HIV clinical trials, 2010-01, Vol.11 (1), p.28-38

2010

Volltextzugriff (PDF)

Pharmacokinetic interactions between buprenorphine/naloxone and

Drug and alcohol dependence, 2009-12, Vol.105 (3), p.234-239

2009

Volltextzugriff (PDF)

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers

Biopharmaceutics & drug disposition, 1999-09, Vol.20 (6), p.285-291

1999

Volltextzugriff (PDF)

Isotype choice for chimeric antibodies affects binding properties

The Journal of biological chemistry, 1994-04, Vol.269 (17), p.13048-13055

1994

Volltextzugriff (PDF)

The effect of selected drugs on first-stage radioemesis in beagle dogs

Radiation research, 1979-05, Vol.78 (2), p.286

1979

Volltextzugriff (PDF)

Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection

AAPS PharmSci, 2000, Vol.2 (1), p.E1-8

2000

Volltextzugriff (PDF)

Acute toxicity of latex microspheres

Toxicology letters, 1981-01, Vol.9 (2), p.165-170

1981

Volltextzugriff (PDF)

1 – 25 von 98

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(85)

Publikationsform

Sprache

Englisch
(98)
Japanisch
(24)

Erscheinungsjahr

n.n

Thema

Science & Technology
(77)
Life Sciences & Biomedicine
(64)
Humans
(55)
Biological And Medical Sciences
(29)
Female
(28)
Male
(28)
Adult
(21)
Medical Sciences
(20)
Animals
(15)
Pharmacology & Pharmacy
(14)
Science & Technology - Other Topics
(14)
Infectious Diseases
(13)
Middle Aged
(13)
Multidisciplinary Sciences
(13)
Genomics
(12)
Fundamental And Applied Biological Sciences. Psychology
(11)
Adolescent
(9)
Anti-Hiv Agents - Administration & Dosage
(9)
Hiv Infections - Drug Therapy
(9)
Microbiology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Interaction of Ritonavir-Boosted Tipranavir with Loperamide Does Not Result in Loperamide-Associated Neurologic Side Effects in Healthy Volunteers

Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers

Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open‐Label, Fixed‐Sequence, Crossover Study

Interaction Studies of Tipranavir-Ritonavir with Clarithromycin, Fluconazole, and Rifabutin in Healthy Volunteers

Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes

Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers

Steady-State Disposition of the Nonpeptidic Protease Inhibitor Tipranavir when Coadministered with Ritonavir

Nevirapine Extended-Release Formulation Tablets in HIV-1–Infected Children—Long-term Follow-up

Clinical Assessment of Potential Drug Interactions of Faldaprevir, a Hepatitis C Virus Protease Inhibitor, With Darunavir/Ritonavir, Efavirenz, and Tenofovir

Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis

Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation

Steady-state Pharmacokinetics of Nevirapine Extended-release Tablets in HIV-1–infected Children and Adolescents: An Open-label, Multiple-dose, Cross-over Study

Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity : sub-analysis from RESIST

Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection

Nevirapine Extended-Release Formulation Tablets in HIV-1–Infected Children—Long-term Follow-up: Table 1

Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers

Pharmacokinetic Characterization of Three Doses of Tipranavir Boosted with Ritonavir on Highly Active Antiretroviral Therapy in Treatment-Experienced HIV-1 Patients

Pharmacokinetic interactions between buprenorphine/naloxone and

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers

Isotype choice for chimeric antibodies affects binding properties

The effect of selected drugs on first-stage radioemesis in beagle dogs

Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection

Acute toxicity of latex microspheres

Suchergebnisse filtern